59 assets in Classic Hodgkin Lymphoma

Therapeutic assets addressing Classic Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dacarbazine Classic Hodgkin Lymphoma	City of Hope Medical Center	P3	BB (69)
Adriamycin Classic Hodgkin Lymphoma	Michael Spinner, MD	P3	BB (68)
Etoposide Classic Hodgkin Lymphoma	Masonic Cancer Center, University of Minnesota	P3	BB (68)
Vinblastine Classic Hodgkin Lymphoma	University of Washington	P2	BB (68)
Cyclophosphamide Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	BB (67)
Tislelizumab Classic Hodgkin Lymphoma	Children's Cancer Group, China	P3	BB (67)
Brentuximab Vedotin Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	BB (66)
Carboplatin Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	BB (66)
Gls-010 Classic Hodgkin Lymphoma	Guangzhou Gloria Biosciences Co., Ltd.	P3	BB (66)
Isocyclophosphamide Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	BB (66)
Bendamustine Classic Hodgkin Lymphoma	New York Medical College	P3	BB (65)
Epirubicin Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	BB (65)
Nivolumab Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	BB (65)
Pegfilgrastim Classic Hodgkin Lymphoma	Michael Spinner, MD	P3	BB (65)
Pembrolizumab Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	BB (65)
Prednisone Classic Hodgkin Lymphoma	Children's Cancer Group, China	P3	BB (65)
Begev Classic Hodgkin Lymphoma	Cairo University	P3	BB (64)
(+)-Vincristine Classic Hodgkin Lymphoma	Sun Yat-sen University	P3	BB (64)
Bleomycin Classic Hodgkin Lymphoma	Helwan University	P3	B (62)
Cis-Diamminedichloroplatinum Ii Classic Hodgkin Lymphoma	Cairo University	P3	B (62)
Dexasone Classic Hodgkin Lymphoma	Cairo University	P3	B (62)
imm01 Classic Hodgkin Lymphoma	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P3	B (62)
Vinorelbine Ditartrate Classic Hodgkin Lymphoma	Michael Spinner, MD	P3	B (62)
Cytarabine Classic Hodgkin Lymphoma	Masonic Cancer Center, University of Minnesota	P2	B (61)
Procarbazine Classic Hodgkin Lymphoma	Merck Sharp & Dohme LLC	P3	B (61)
Azacitidine Classic Hodgkin Lymphoma	Navy General Hospital, Beijing	P2	B (60)
Nivestim Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Ibrutinib Classic Hodgkin Lymphoma	Ohio State University Comprehensive Cancer Center	P2	B (57)
Rituximab Classic Hodgkin Lymphoma	Yale University	P2	B (57)
Vincristine Sulfate Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P3	B (57)
Zemirciclib Classic Hodgkin Lymphoma	AstraZeneca	P2	B (57)
Bedamustine Classic Hodgkin Lymphoma	Children's Cancer Group, China	P2/3	CCC (55)
Ipilimumab Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Camustine Classic Hodgkin Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Decitabine Classic Hodgkin Lymphoma	Chinese PLA General Hospital	P2	CCC (53)
Fludarabine Classic Hodgkin Lymphoma	New York Medical College	P1/2	CCC (53)
Melphalan Classic Hodgkin Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Penpulimab Classic Hodgkin Lymphoma	Sun Yat-sen University	P2	CCC (53)
Tucidinostat Classic Hodgkin Lymphoma	Chinese PLA General Hospital	P2	CCC (53)
Zimberelimab Classic Hodgkin Lymphoma	Sun Yat-sen University	P2	CCC (53)
ak129 Classic Hodgkin Lymphoma	Akeso	P1/2	CC (45)
Docetaxel Classic Hodgkin Lymphoma	NuCana plc	P1/2	CC (45)
Everolimus Classic Hodgkin Lymphoma	University of Pennsylvania	P1/2	CC (45)
gen3017 Classic Hodgkin Lymphoma	Genmab	P1/2	CC (45)
ilb2109 Classic Hodgkin Lymphoma	Innolake Biopharm	P1/2	CC (45)
Ligufalimab Classic Hodgkin Lymphoma	Akeso	P1/2	CC (45)
Toripalimab Classic Hodgkin Lymphoma	Innolake Biopharm	P1/2	CC (45)
Vorinostat Classic Hodgkin Lymphoma	City of Hope Medical Center	P1	CC (43)
Itacitinib Classic Hodgkin Lymphoma	University of Pennsylvania	P1/2	CC (42)
Autologous Cd30.Car-T Classic Hodgkin Lymphoma	Tessa Therapeutics	P1	CC (41)

Showing 1 to 50 of 59 assets

PreviousPage 1 of 2Next